Login to Your Account



Wellstat, Sanofi Ink $350M Deal for Phase II Insulin Sensitizer

By Donna Young


Thursday, October 22, 2009
Privately held Wellstat Therapeutics Corp. stands to gain up to $350 million, including an undisclosed up-front payment, in exchange for global rights to its Type II diabetes oral insulin sensitizer PN2034 and related compounds in a development and commercialization deal with Sanofi-Aventis Group SA, which sought the licensing agreement to beef up its diabetes platform. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription